Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant‐DNA hepatitis B vaccine
Identifieur interne : 000584 ( Istex/Corpus ); précédent : 000583; suivant : 000585Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant‐DNA hepatitis B vaccine
Auteurs : R. A. Heijtink ; J. Kruining ; P. Van Bergen ; S. De Rave ; J. Van Hattum ; M. Schutten ; A. D. M. E. OsterhausSource :
- Journal of Medical Virology [ 0146-6615 ] ; 2002-03.
Abstract
A human monoclonal antibody type IgG4, designated 1Ff4, was obtained by Epstein Barr virus transformation of peripheral blood lymphocytes from a hepatitis B vaccinee (HB‐VAX: plasma‐derived vaccine) after one boost of yeast recombinant DNA derived vaccine (Engerix‐B). 1Ff4 binds preferentially to HBsAg/adw2 and HBsAg/ayw1. In binding experiments, it competes with antibodies induced by vaccination with HB‐VAX‐DNA (yeast recombinant) and HB‐VAX (plasma‐derived vaccine). 1Ff4 competes in part with a monoclonal antibody for the w/r region. Partial inhibition of binding of HBsAg/adw2 to solid phase anti‐HBs was detected, resembling inhibition obtained using other human monoclonal specific for the “a”‐loop. 1Ff4 does not bind to linear peptides covering the two “a”‐loops or to an adw2/G145R mutant, its binding to wild type HBsAg strongly depends on the presence of disulphide bonds. In a large series of HBsAg‐positive samples from an endemic area, 1Ff4 antibodies were successfully used to discriminate between an adw2 and an adrq+ strain. The characterisation of 1Ff4 and other human monoclonal anti‐HBs antibodies may help to understand the fine specificity of protective antibodies elicited by immunization. J. Med. Virol. 66:304‐311, 2002. © 2002 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jmv.2146
Links to Exploration step
ISTEX:2D0D41BE6B34DA1B0F80FC7647C66386D93201E2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant‐DNA hepatitis B vaccine</title><author><name sortKey="Heijtink, R A" sort="Heijtink, R A" uniqKey="Heijtink R" first="R. A." last="Heijtink">R. A. Heijtink</name><affiliation><mods:affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: Heijtink@viro.fgg.eur.nl</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Department of Virology, Erasmus University, Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.===</mods:affiliation></affiliation></author><author><name sortKey="Kruining, J" sort="Kruining, J" uniqKey="Kruining J" first="J." last="Kruining">J. Kruining</name><affiliation><mods:affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Van Bergen, P" sort="Van Bergen, P" uniqKey="Van Bergen P" first="P." last="Van Bergen">P. Van Bergen</name><affiliation><mods:affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="De Rave, S" sort="De Rave, S" uniqKey="De Rave S" first="S." last="De Rave">S. De Rave</name><affiliation><mods:affiliation>Department of Hepatology and Gastroenterology, Academic Hospital Dijkzigt, Rotterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Van Hattum, J" sort="Van Hattum, J" uniqKey="Van Hattum J" first="J." last="Van Hattum">J. Van Hattum</name><affiliation><mods:affiliation>Department of Hepato‐gastroenterology, Academic Hospital Utrecht, Utrecht, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Schutten, M" sort="Schutten, M" uniqKey="Schutten M" first="M." last="Schutten">M. Schutten</name><affiliation><mods:affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Osterhaus, A D M E" sort="Osterhaus, A D M E" uniqKey="Osterhaus A" first="A. D. M. E." last="Osterhaus">A. D. M. E. Osterhaus</name><affiliation><mods:affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2D0D41BE6B34DA1B0F80FC7647C66386D93201E2</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/jmv.2146</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-F3G8DCGQ-T/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000584</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000584</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant‐DNA hepatitis B vaccine</title><author><name sortKey="Heijtink, R A" sort="Heijtink, R A" uniqKey="Heijtink R" first="R. A." last="Heijtink">R. A. Heijtink</name><affiliation><mods:affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: Heijtink@viro.fgg.eur.nl</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Department of Virology, Erasmus University, Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.===</mods:affiliation></affiliation></author><author><name sortKey="Kruining, J" sort="Kruining, J" uniqKey="Kruining J" first="J." last="Kruining">J. Kruining</name><affiliation><mods:affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Van Bergen, P" sort="Van Bergen, P" uniqKey="Van Bergen P" first="P." last="Van Bergen">P. Van Bergen</name><affiliation><mods:affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="De Rave, S" sort="De Rave, S" uniqKey="De Rave S" first="S." last="De Rave">S. De Rave</name><affiliation><mods:affiliation>Department of Hepatology and Gastroenterology, Academic Hospital Dijkzigt, Rotterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Van Hattum, J" sort="Van Hattum, J" uniqKey="Van Hattum J" first="J." last="Van Hattum">J. Van Hattum</name><affiliation><mods:affiliation>Department of Hepato‐gastroenterology, Academic Hospital Utrecht, Utrecht, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Schutten, M" sort="Schutten, M" uniqKey="Schutten M" first="M." last="Schutten">M. Schutten</name><affiliation><mods:affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Osterhaus, A D M E" sort="Osterhaus, A D M E" uniqKey="Osterhaus A" first="A. D. M. E." last="Osterhaus">A. D. M. E. Osterhaus</name><affiliation><mods:affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Medical Virology</title><title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title><idno type="ISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><imprint><biblScope unit="vol">66</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="304">304</biblScope><biblScope unit="page" to="311">311</biblScope><biblScope unit="page-count">8</biblScope><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-03">2002-03</date></imprint><idno type="ISSN">0146-6615</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0146-6615</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A human monoclonal antibody type IgG4, designated 1Ff4, was obtained by Epstein Barr virus transformation of peripheral blood lymphocytes from a hepatitis B vaccinee (HB‐VAX: plasma‐derived vaccine) after one boost of yeast recombinant DNA derived vaccine (Engerix‐B). 1Ff4 binds preferentially to HBsAg/adw2 and HBsAg/ayw1. In binding experiments, it competes with antibodies induced by vaccination with HB‐VAX‐DNA (yeast recombinant) and HB‐VAX (plasma‐derived vaccine). 1Ff4 competes in part with a monoclonal antibody for the w/r region. Partial inhibition of binding of HBsAg/adw2 to solid phase anti‐HBs was detected, resembling inhibition obtained using other human monoclonal specific for the “a”‐loop. 1Ff4 does not bind to linear peptides covering the two “a”‐loops or to an adw2/G145R mutant, its binding to wild type HBsAg strongly depends on the presence of disulphide bonds. In a large series of HBsAg‐positive samples from an endemic area, 1Ff4 antibodies were successfully used to discriminate between an adw2 and an adrq+ strain. The characterisation of 1Ff4 and other human monoclonal anti‐HBs antibodies may help to understand the fine specificity of protective antibodies elicited by immunization. J. Med. Virol. 66:304‐311, 2002. © 2002 Wiley‐Liss, Inc.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>monoclonal</json:string><json:string>hbsag</json:string><json:string>recombinant</json:string><json:string>epitope</json:string><json:string>heijtink</json:string><json:string>monoclonal antibody</json:string><json:string>vaccine</json:string><json:string>human monoclonal antibody</json:string><json:string>characterisation</json:string><json:string>solid phase</json:string><json:string>adw2</json:string><json:string>virol</json:string><json:string>surface antigen</json:string><json:string>discontinuous epitope</json:string><json:string>polyclonal</json:string><json:string>hepatect</json:string><json:string>assay</json:string><json:string>subtypes</json:string><json:string>recombinant hbsag</json:string><json:string>hepatitis</json:string><json:string>recombinant vaccine</json:string><json:string>endemic area</json:string><json:string>chronic hepatitis</json:string><json:string>polyclonal antibody</json:string><json:string>peptide</json:string><json:string>organon teknika</json:string><json:string>wild type</json:string><json:string>hbsag subtypes</json:string><json:string>solution assay</json:string><json:string>mouse monoclonal</json:string><json:string>present study</json:string><json:string>amino acid</json:string><json:string>antibody</json:string></teeft></keywords><author><json:item><name>R.A. Heijtink</name><affiliations><json:string>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</json:string><json:string>E-mail: Heijtink@viro.fgg.eur.nl</json:string><json:string>Correspondence address: Department of Virology, Erasmus University, Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.===</json:string></affiliations></json:item><json:item><name>J. Kruining</name><affiliations><json:string>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</json:string></affiliations></json:item><json:item><name>P. van Bergen</name><affiliations><json:string>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</json:string></affiliations></json:item><json:item><name>S. de Rave</name><affiliations><json:string>Department of Hepatology and Gastroenterology, Academic Hospital Dijkzigt, Rotterdam, The Netherlands</json:string></affiliations></json:item><json:item><name>J. van Hattum</name><affiliations><json:string>Department of Hepato‐gastroenterology, Academic Hospital Utrecht, Utrecht, The Netherlands</json:string></affiliations></json:item><json:item><name>M. Schutten</name><affiliations><json:string>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</json:string></affiliations></json:item><json:item><name>A.D.M.E. Osterhaus</name><affiliations><json:string>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>HBsAg</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>anti‐HBs</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>monoclonal</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>hybridoma</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>variant</value></json:item></subject><articleId><json:string>JMV2146</json:string></articleId><arkIstex>ark:/67375/WNG-F3G8DCGQ-T</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>A human monoclonal antibody type IgG4, designated 1Ff4, was obtained by Epstein Barr virus transformation of peripheral blood lymphocytes from a hepatitis B vaccinee (HB‐VAX: plasma‐derived vaccine) after one boost of yeast recombinant DNA derived vaccine (Engerix‐B). 1Ff4 binds preferentially to HBsAg/adw2 and HBsAg/ayw1. In binding experiments, it competes with antibodies induced by vaccination with HB‐VAX‐DNA (yeast recombinant) and HB‐VAX (plasma‐derived vaccine). 1Ff4 competes in part with a monoclonal antibody for the w/r region. Partial inhibition of binding of HBsAg/adw2 to solid phase anti‐HBs was detected, resembling inhibition obtained using other human monoclonal specific for the “a”‐loop. 1Ff4 does not bind to linear peptides covering the two “a”‐loops or to an adw2/G145R mutant, its binding to wild type HBsAg strongly depends on the presence of disulphide bonds. In a large series of HBsAg‐positive samples from an endemic area, 1Ff4 antibodies were successfully used to discriminate between an adw2 and an adrq+ strain. The characterisation of 1Ff4 and other human monoclonal anti‐HBs antibodies may help to understand the fine specificity of protective antibodies elicited by immunization. J. Med. Virol. 66:304‐311, 2002. © 2002 Wiley‐Liss, Inc.</abstract><qualityIndicators><score>7.544</score><pdfWordCount>3336</pdfWordCount><pdfCharCount>21714</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>8</pdfPageCount><pdfPageSize>593 x 792 pts</pdfPageSize><pdfWordsPerPage>417</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>184</abstractWordCount><abstractCharCount>1274</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant‐DNA hepatitis B vaccine</title><pmid><json:string>11793381</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Journal of Medical Virology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1096-9071</json:string></doi><issn><json:string>0146-6615</json:string></issn><eissn><json:string>1096-9071</json:string></eissn><publisherId><json:string>JMV</json:string></publisherId><volume>66</volume><issue>3</issue><pages><first>304</first><last>311</last><total>8</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1986</json:string><json:string>2002</json:string></date><geogName></geogName><orgName><json:string>Academic Hospital Dijkzigt, Rotterdam, The Netherlands Department of Hepato</json:string><json:string>Academic Hospital Utrecht, Utrecht, The Netherlands</json:string><json:string>Biotech</json:string><json:string>Department of Virology, Erasmus University, Rotterdam</json:string><json:string>Wiley-Liss, Inc</json:string><json:string>LISS, INC.</json:string><json:string>Abbott Laboratories</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>J. Kruining</json:string><json:string>J.A. Hellings</json:string><json:string>P.O. Box</json:string><json:string>R.A. Heijtink</json:string><json:string>S. de Rave</json:string><json:string>J. Med</json:string><json:string>Rotterdam</json:string><json:string>A.D.M.E. Osterhaus</json:string></persName><placeName><json:string>Germany</json:string><json:string>UK</json:string><json:string>Europe</json:string><json:string>Indonesia</json:string><json:string>Puri</json:string><json:string>Netherlands</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Foung et al., 1984</json:string><json:string>Cooreman et al., 1999</json:string><json:string>Gerlich et al., 1993</json:string><json:string>Jilg et al., 1984</json:string><json:string>Heijtink et al., 1999</json:string><json:string>Heijtink et al.</json:string><json:string>Heijtink et al., 2001</json:string><json:string>Gregorek et al., 2000b</json:string><json:string>Aalberse et al., 1993</json:string><json:string>Heijtink et al., 2000</json:string><json:string>Heijtink et al., 1995, 1999</json:string><json:string>Harlow and Lane, 1988</json:string><json:string>Samuel et al., 1993</json:string><json:string>Ehrlich et al., 1992</json:string><json:string>Gregorek et al., 2000a</json:string><json:string>Paulij et al., 1999</json:string><json:string>Chen et al. [1996]</json:string><json:string>Okamoto et al., 1986</json:string><json:string>Heijtink et al., 1985</json:string><json:string>Panda et al., 1991</json:string><json:string>Courouce-Pauty et al., 1976</json:string><json:string>Heijtink et al., 1995</json:string><json:string>Desgranges et al., 1987</json:string><json:string>Gavilanes et al., 1990</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-F3G8DCGQ-T</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - virology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Virology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2002</publicationDate><copyrightDate>2002</copyrightDate><doi><json:string>10.1002/jmv.2146</json:string></doi><id>2D0D41BE6B34DA1B0F80FC7647C66386D93201E2</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-F3G8DCGQ-T/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-F3G8DCGQ-T/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-F3G8DCGQ-T/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant‐DNA hepatitis B vaccine</title><title level="a" type="short" xml:lang="en">Characterisation of a Hu‐McAb Anti‐HBs</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><licence>Copyright © 2002 Wiley‐Liss, Inc.</licence></availability><date type="published" when="2002-03"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant‐DNA hepatitis B vaccine</title><title level="a" type="short" xml:lang="en">Characterisation of a Hu‐McAb Anti‐HBs</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">R.A.</forename><surname>Heijtink</surname></persName><email>Heijtink@viro.fgg.eur.nl</email><affiliation><orgName type="department">Department of Virology</orgName><orgName type="institution">Erasmus University Rotterdam</orgName><address><addrLine>Rotterdam</addrLine><addrLine>The Netherlands</addrLine><country key="NL" xml:lang="en">THE NETHERLANDS</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">J.</forename><surname>Kruining</surname></persName><affiliation><orgName type="department">Department of Virology</orgName><orgName type="institution">Erasmus University Rotterdam</orgName><address><addrLine>Rotterdam</addrLine><addrLine>The Netherlands</addrLine><country key="NL" xml:lang="en">THE NETHERLANDS</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">P.</forename><surname>van Bergen</surname></persName><affiliation><orgName type="department">Department of Virology</orgName><orgName type="institution">Erasmus University Rotterdam</orgName><address><addrLine>Rotterdam</addrLine><addrLine>The Netherlands</addrLine><country key="NL" xml:lang="en">THE NETHERLANDS</country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">S.</forename><surname>de Rave</surname></persName><affiliation><orgName type="department">Department of Hepatology and Gastroenterology</orgName><orgName type="institution">Academic Hospital Dijkzigt</orgName><address><addrLine>Rotterdam</addrLine><addrLine>The Netherlands</addrLine><country key="NL" xml:lang="en">THE NETHERLANDS</country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">J.</forename><surname>van Hattum</surname></persName><affiliation><orgName type="department">Department of Hepato‐gastroenterology</orgName><orgName type="institution">Academic Hospital Utrecht</orgName><address><addrLine>Utrecht</addrLine><addrLine>The Netherlands</addrLine><country key="NL" xml:lang="en">THE NETHERLANDS</country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">M.</forename><surname>Schutten</surname></persName><affiliation><orgName type="department">Department of Virology</orgName><orgName type="institution">Erasmus University Rotterdam</orgName><address><addrLine>Rotterdam</addrLine><addrLine>The Netherlands</addrLine><country key="NL" xml:lang="en">THE NETHERLANDS</country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">A.D.M.E.</forename><surname>Osterhaus</surname></persName><affiliation><orgName type="department">Department of Virology</orgName><orgName type="institution">Erasmus University Rotterdam</orgName><address><addrLine>Rotterdam</addrLine><addrLine>The Netherlands</addrLine><country key="NL" xml:lang="en">THE NETHERLANDS</country></address></affiliation></author><idno type="istex">2D0D41BE6B34DA1B0F80FC7647C66386D93201E2</idno><idno type="ark">ark:/67375/WNG-F3G8DCGQ-T</idno><idno type="DOI">10.1002/jmv.2146</idno><idno type="unit">JMV2146</idno><idno type="toTypesetVersion">file:JMV.JMV2146.pdf</idno></analytic><monogr><title level="j" type="main">Journal of Medical Virology</title><title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title><idno type="pISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><idno type="book-DOI">10.1002/(ISSN)1096-9071</idno><idno type="book-part-DOI">10.1002/jmv.v66:3</idno><idno type="product">JMV</idno><imprint><biblScope unit="vol">66</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="304">304</biblScope><biblScope unit="page" to="311">311</biblScope><biblScope unit="page-count">8</biblScope><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-03"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>A human monoclonal antibody type IgG4, designated 1Ff4, was obtained by Epstein Barr virus transformation of peripheral blood lymphocytes from a hepatitis B vaccinee (HB‐VAX: plasma‐derived vaccine) after one boost of yeast recombinant DNA derived vaccine (Engerix‐B). 1Ff4 binds preferentially to HBsAg/<hi rend="italic">adw</hi><hi rend="subscript">2</hi> and HBsAg/<hi rend="italic">ayw</hi><hi rend="subscript">1</hi>. In binding experiments, it competes with antibodies induced by vaccination with HB‐VAX‐DNA (yeast recombinant) and HB‐VAX (plasma‐derived vaccine). 1Ff4 competes in part with a monoclonal antibody for the w/r region. Partial inhibition of binding of HBsAg/<hi rend="italic">adw</hi><hi rend="subscript">2</hi> to solid phase anti‐HBs was detected, resembling inhibition obtained using other human monoclonal specific for the “a”‐loop. 1Ff4 does not bind to linear peptides covering the two “a”‐loops or to an <hi rend="italic">adw</hi><hi rend="subscript">2</hi>/G145R mutant, its binding to wild type HBsAg strongly depends on the presence of disulphide bonds. In a large series of HBsAg‐positive samples from an endemic area, 1Ff4 antibodies were successfully used to discriminate between an <hi rend="italic">adw</hi><hi rend="subscript">2</hi> and an adrq+ strain. The characterisation of 1Ff4 and other human monoclonal anti‐HBs antibodies may help to understand the fine specificity of protective antibodies elicited by immunization. J. Med. Virol. 66:304‐311, 2002. © 2002 Wiley‐Liss, Inc.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="kwd1">HBsAg</term><term xml:id="kwd2">anti‐HBs</term><term xml:id="kwd3">monoclonal</term><term xml:id="kwd4">hybridoma</term><term xml:id="kwd5">variant</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-F3G8DCGQ-T/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1096-9071</doi><issn type="print">0146-6615</issn><issn type="electronic">1096-9071</issn><idGroup><id type="product" value="JMV"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="JOURNAL OF MEDICAL VIROLOGY">Journal of Medical Virology</title><title type="short">J. Med. Virol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/jmv.v66:3</doi><numberingGroup><numbering type="journalVolume" number="66">66</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2002-03">March 2002</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="3" status="forIssue"><doi origin="wiley" registered="yes">10.1002/jmv.2146</doi><idGroup><id type="unit" value="JMV2146"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><copyright ownership="publisher">Copyright © 2002 Wiley‐Liss, Inc.</copyright><eventGroup><event type="manuscriptAccepted" date="2001-07-16"></event><event type="firstOnline" date="2002-01-04"></event><event type="publishedOnlineFinalForm" date="2002-01-04"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-15"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-20"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-30"></event></eventGroup><numberingGroup><numbering type="pageFirst">304</numbering><numbering type="pageLast">311</numbering></numberingGroup><correspondenceTo>Department of Virology, Erasmus University, Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.===</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:JMV.JMV2146.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="6"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="22"></count><count type="wordTotal" number="847"></count></countGroup><titleGroup><title type="main" xml:lang="en">Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant‐DNA hepatitis B vaccine</title><title type="short" xml:lang="en">Characterisation of a Hu‐McAb Anti‐HBs</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>R.A.</givenNames><familyName>Heijtink</familyName></personName><contactDetails><email>Heijtink@viro.fgg.eur.nl</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>J.</givenNames><familyName>Kruining</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>P.</givenNames><familyName>van Bergen</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>S.</givenNames><familyName>de Rave</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>J.</givenNames><familyName>van Hattum</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>M.</givenNames><familyName>Schutten</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>A.D.M.E.</givenNames><familyName>Osterhaus</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="NL" type="organization"><unparsedAffiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="NL" type="organization"><unparsedAffiliation>Department of Hepatology and Gastroenterology, Academic Hospital Dijkzigt, Rotterdam, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="NL" type="organization"><unparsedAffiliation>Department of Hepato‐gastroenterology, Academic Hospital Utrecht, Utrecht, The Netherlands</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">HBsAg</keyword><keyword xml:id="kwd2">anti‐HBs</keyword><keyword xml:id="kwd3">monoclonal</keyword><keyword xml:id="kwd4">hybridoma</keyword><keyword xml:id="kwd5">variant</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>A human monoclonal antibody type IgG4, designated 1Ff4, was obtained by Epstein Barr virus transformation of peripheral blood lymphocytes from a hepatitis B vaccinee (HB‐VAX: plasma‐derived vaccine) after one boost of yeast recombinant DNA derived vaccine (Engerix‐B). 1Ff4 binds preferentially to HBsAg/<i>adw</i><sub>2</sub> and HBsAg/<i>ayw</i><sub>1</sub>. In binding experiments, it competes with antibodies induced by vaccination with HB‐VAX‐DNA (yeast recombinant) and HB‐VAX (plasma‐derived vaccine). 1Ff4 competes in part with a monoclonal antibody for the w/r region. Partial inhibition of binding of HBsAg/<i>adw</i><sub>2</sub> to solid phase anti‐HBs was detected, resembling inhibition obtained using other human monoclonal specific for the “a”‐loop. 1Ff4 does not bind to linear peptides covering the two “a”‐loops or to an <i>adw</i><sub>2</sub>/G145R mutant, its binding to wild type HBsAg strongly depends on the presence of disulphide bonds. In a large series of HBsAg‐positive samples from an endemic area, 1Ff4 antibodies were successfully used to discriminate between an <i>adw</i><sub>2</sub> and an adrq+ strain. The characterisation of 1Ff4 and other human monoclonal anti‐HBs antibodies may help to understand the fine specificity of protective antibodies elicited by immunization. J. Med. Virol. 66:304‐311, 2002. © 2002 Wiley‐Liss, Inc.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant‐DNA hepatitis B vaccine</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Characterisation of a Hu‐McAb Anti‐HBs</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant‐DNA hepatitis B vaccine</title></titleInfo><name type="personal"><namePart type="given">R.A.</namePart><namePart type="family">Heijtink</namePart><affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</affiliation><affiliation>E-mail: Heijtink@viro.fgg.eur.nl</affiliation><affiliation>Correspondence address: Department of Virology, Erasmus University, Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.===</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Kruining</namePart><affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">van Bergen</namePart><affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">de Rave</namePart><affiliation>Department of Hepatology and Gastroenterology, Academic Hospital Dijkzigt, Rotterdam, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">van Hattum</namePart><affiliation>Department of Hepato‐gastroenterology, Academic Hospital Utrecht, Utrecht, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Schutten</namePart><affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.D.M.E.</namePart><namePart type="family">Osterhaus</namePart><affiliation>Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2002-03</dateIssued><dateValid encoding="w3cdtf">2001-07-16</dateValid><copyrightDate encoding="w3cdtf">2002</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">6</extent><extent unit="tables">0</extent><extent unit="references">22</extent><extent unit="words">847</extent></physicalDescription><abstract lang="en">A human monoclonal antibody type IgG4, designated 1Ff4, was obtained by Epstein Barr virus transformation of peripheral blood lymphocytes from a hepatitis B vaccinee (HB‐VAX: plasma‐derived vaccine) after one boost of yeast recombinant DNA derived vaccine (Engerix‐B). 1Ff4 binds preferentially to HBsAg/adw2 and HBsAg/ayw1. In binding experiments, it competes with antibodies induced by vaccination with HB‐VAX‐DNA (yeast recombinant) and HB‐VAX (plasma‐derived vaccine). 1Ff4 competes in part with a monoclonal antibody for the w/r region. Partial inhibition of binding of HBsAg/adw2 to solid phase anti‐HBs was detected, resembling inhibition obtained using other human monoclonal specific for the “a”‐loop. 1Ff4 does not bind to linear peptides covering the two “a”‐loops or to an adw2/G145R mutant, its binding to wild type HBsAg strongly depends on the presence of disulphide bonds. In a large series of HBsAg‐positive samples from an endemic area, 1Ff4 antibodies were successfully used to discriminate between an adw2 and an adrq+ strain. The characterisation of 1Ff4 and other human monoclonal anti‐HBs antibodies may help to understand the fine specificity of protective antibodies elicited by immunization. J. Med. Virol. 66:304‐311, 2002. © 2002 Wiley‐Liss, Inc.</abstract><subject lang="en"><genre>keywords</genre><topic>HBsAg</topic><topic>anti‐HBs</topic><topic>monoclonal</topic><topic>hybridoma</topic><topic>variant</topic></subject><relatedItem type="host"><titleInfo><title>Journal of Medical Virology</title></titleInfo><titleInfo type="abbreviated"><title>J. Med. Virol.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0146-6615</identifier><identifier type="eISSN">1096-9071</identifier><identifier type="DOI">10.1002/(ISSN)1096-9071</identifier><identifier type="PublisherID">JMV</identifier><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>304</start><end>311</end><total>8</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Allergen‐specific IgG4 in atopic disease</title></titleInfo><name type="personal"><namePart type="given">RC</namePart><namePart type="family">Aalberse</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Van Millingen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KY</namePart><namePart type="family">Tan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SO</namePart><namePart type="family">Stapel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Aalberse RC, Van Millingen F, Tan KY, Stapel SO. 1993. Allergen‐specific IgG4 in atopic disease. Allergy 48: 559–569.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>559</start><end>569</end></extent></part><relatedItem type="host"><titleInfo><title>Allergy</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>559</start><end>569</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library</title></titleInfo><name type="personal"><namePart type="given">Y‐CJ</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Delbrook</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Dealwis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Mimms</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IK</namePart><namePart type="family">Mushahwar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Mandecki</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chen Y‐CJ, Delbrook K, Dealwis C, Mimms L, Mushahwar IK, Mandecki W. 1996. Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. Proc Natl Acad Sci USA 93: 1997–2001.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>1997</start><end>2001</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci USA</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>1997</start><end>2001</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Characterization of the reactivity pattern of murine monoclonal antibodies against wild‐type hepatitis B surface antigen to G145R and other naturally occurring “a” loop escape mutations</title></titleInfo><name type="personal"><namePart type="given">MP</namePart><namePart type="family">Cooreman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MH</namePart><namePart type="family">Roosmalen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Te Morsche</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CMG</namePart><namePart type="family">Sünnen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EME</namePart><namePart type="family">Schoondermark van de Ven</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JBMJ</namePart><namePart type="family">Jansen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GNJ</namePart><namePart type="family">Tytgat</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PLM</namePart><namePart type="family">De Wit</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WP</namePart><namePart type="family">Paulij</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cooreman MP, Roosmalen MH, Te Morsche R, Sünnen CMG, Schoondermark van de Ven EME, Jansen JBMJ, Tytgat GNJ, De Wit PLM, Paulij WP. 1999. Characterization of the reactivity pattern of murine monoclonal antibodies against wild‐type hepatitis B surface antigen to G145R and other naturally occurring “a” loop escape mutations. Hepatology 30: 1287–1292.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>1287</start><end>1292</end></extent></part><relatedItem type="host"><titleInfo><title>Hepatology</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>1287</start><end>1292</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>HBsAg antigenic subtypes</title></titleInfo><name type="personal"><namePart type="given">A‐M</namePart><namePart type="family">Couroucé‐Pauty</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PV</namePart><namePart type="family">Holland</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JY</namePart><namePart type="family">Muller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Soulier</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Couroucé‐Pauty A‐M, Holland PV, Muller JY, Soulier JP. 1976. HBsAg antigenic subtypes. Bibliothec Haematol 42: 1.</note><part><date>1976</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>1</start></extent></part><relatedItem type="host"><titleInfo><title>Bibliothec Haematol</title></titleInfo><part><date>1976</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>High affinity human monoclonal antibodies directed against hepatitis B surface antigen</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Desgranges</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Paire</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Pichoud</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Souche</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Frommel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Trepo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Desgranges C, Paire J, Pichoud C, Souche S, Frommel D, Trepo C. 1987. High affinity human monoclonal antibodies directed against hepatitis B surface antigen. J Virol Methods 16: 281–292.</note><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>281</start><end>292</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol Methods</title></titleInfo><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>281</start><end>292</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Characterization of human monoclonal antibodies directed against hepatitis B surface antigen</title></titleInfo><name type="personal"><namePart type="given">PH</namePart><namePart type="family">Ehrlich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ZA</namePart><namePart type="family">Moustafa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Justice</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Harfeldt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RL</namePart><namePart type="family">Kelley</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Östberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ehrlich PH, Moustafa ZA, Justice JC, Harfeldt E, Kelley RL, Östberg L. 1992. Characterization of human monoclonal antibodies directed against hepatitis B surface antigen. Hum Antibod Hybrid 3: 2–7.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>2</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Hum Antibod Hybrid</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>2</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Rescue of human monoclonal antibody production from an EBV‐transformed B cell line by fusion to a human‐mouse hybridoma</title></titleInfo><name type="personal"><namePart type="given">SKH</namePart><namePart type="family">Foung</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Perkins</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Raubitsek</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Larrick</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Lizak</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Fishwild</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EG</namePart><namePart type="family">Engleman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FC</namePart><namePart type="family">Grumet</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Foung SKH, Perkins S, Raubitsek A, Larrick J, Lizak G, Fishwild D, Engleman EG, Grumet FC. 1984. Rescue of human monoclonal antibody production from an EBV‐transformed B cell line by fusion to a human‐mouse hybridoma. J Immunol Methods 70: 83–90.</note><part><date>1984</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>83</start><end>90</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunol Methods</title></titleInfo><part><date>1984</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>83</start><end>90</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Hepatitis B surface antigen: Role of lipidsnin maintaining the structural and antigenic properties of protein components</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Gavilanes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Gomez‐Gutierrez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Aracil</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Gonzalez‐Ros</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Ferragut</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Guerrero</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DL</namePart><namePart type="family">Peterson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gavilanes F, Gomez‐Gutierrez J, Aracil M, Gonzalez‐Ros JM, Ferragut JA, Guerrero E, Peterson DL. 1990. Hepatitis B surface antigen: Role of lipidsnin maintaining the structural and antigenic properties of protein components. Biochem J 265: 857–864.</note><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>265</number></detail><extent unit="pages"><start>857</start><end>864</end></extent></part><relatedItem type="host"><titleInfo><title>Biochem J</title></titleInfo><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>265</number></detail><extent unit="pages"><start>857</start><end>864</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Studies on the attachment and penetration of hepatitis B virus</title></titleInfo><name type="personal"><namePart type="given">WH</namePart><namePart type="family">Gerlich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X</namePart><namePart type="family">Lu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KH</namePart><namePart type="family">Heerman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gerlich WH, Lu X, Heerman KH. 1993. Studies on the attachment and penetration of hepatitis B virus. J Hepatol 17(Suppl 3): S10–S14.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 3</number></detail><extent unit="pages"><start>S10</start><end>S14</end></extent></part><relatedItem type="host"><titleInfo><title>J Hepatol</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 3</number></detail><extent unit="pages"><start>S10</start><end>S14</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>The IgG subclass profile of anti‐HBs response in vaccinated children and children seroconverted to natural infection</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Gregorek</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Madalinski</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Woynarowski</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Mikolajewicz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Syczewska</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Socha</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gregorek H, Madalinski K, Woynarowski M, Mikolajewicz J, Syczewska M, Socha J. 2000a. The IgG subclass profile of anti‐HBs response in vaccinated children and children seroconverted to natural infection. Vaccine 18: 1210–1217.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>1210</start><end>1217</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>1210</start><end>1217</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>IgG subclass distribution of hepatitis B surface antigen antibodies induced in children with chronic hepatitis B infection after interferon‐alpha therapy</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Gregorek</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Madalinski</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Woynarowski</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Mikolajewicz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Syczewska</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Socha</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gregorek H, Madalinski K, Woynarowski M, Mikolajewicz J, Syczewska M, Socha J. 2000b. IgG subclass distribution of hepatitis B surface antigen antibodies induced in children with chronic hepatitis B infection after interferon‐alpha therapy. J Inf Dis 181: 2059–2062.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>181</number></detail><extent unit="pages"><start>2059</start><end>2062</end></extent></part><relatedItem type="host"><titleInfo><title>J Inf Dis</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>181</number></detail><extent unit="pages"><start>2059</start><end>2062</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Harlow E,Lane D.1988. In:Antibodies: a laboratory manual.Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.</title></titleInfo><note type="citation/reference">Harlow E, Lane D. 1988. In: Antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.</note><name type="personal"><namePart type="given">E</namePart><namePart type="family">Harlow</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Lane</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book</genre><originInfo><publisher>Cold Spring Harbor Laboratory</publisher><place><placeTerm type="text">Cold Spring Harbor, NY</placeTerm></place></originInfo><part><date>1988</date></part></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Immune response after vaccination with recombinant hepatitis B vaccine as compared to that after plasma vaccine</title></titleInfo><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Heijtink</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Kruining</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Bakker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SW</namePart><namePart type="family">Schalm</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Heijtink RA, Kruining J, Bakker M, Schalm SW. 1985. Immune response after vaccination with recombinant hepatitis B vaccine as compared to that after plasma vaccine. Antiviral Res (Suppl1): 273–279.</note><part><date>1985</date><detail type="issue"><caption>no.</caption><number>Suppl1</number></detail><extent unit="pages"><start>273</start><end>279</end></extent></part><relatedItem type="host"><titleInfo><title>Antiviral Res</title></titleInfo><part><date>1985</date><detail type="issue"><caption>no.</caption><number>Suppl1</number></detail><extent unit="pages"><start>273</start><end>279</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Anti‐hepatitis B virus activity of a mixture of two monoclonal antibodies in an “inhibition in solution assay.”</title></titleInfo><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Heijtink</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Kruining</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YAM</namePart><namePart type="family">Weber</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RA</namePart><namePart type="family">De Man</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SW</namePart><namePart type="family">Schalm</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Heijtink RA, Kruining J, Weber YAM, De Man RA, Schalm SW. 1995. Anti‐hepatitis B virus activity of a mixture of two monoclonal antibodies in an “inhibition in solution assay.” Hepatology 22: 1078–1083.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1078</start><end>1083</end></extent></part><relatedItem type="host"><titleInfo><title>Hepatology</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1078</start><end>1083</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>In vivo activity of a mixture of two human monoclonal antibodies (anti‐HBs) in a chronic hepatitis B carrier chimpanzee</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Heijtink</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Paulij</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Van Bergen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Van Roosmalen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Rohm</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Eichentopf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Muchmore</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">De Man</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Osterhaus</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Heijtink R, Paulij W, Van Bergen P, Van Roosmalen M, Rohm D, Eichentopf B, Muchmore E, De Man R, Osterhaus A. 1999. In vivo activity of a mixture of two human monoclonal antibodies (anti‐HBs) in a chronic hepatitis B carrier chimpanzee. J Gen Virol 80: 1529–1535.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>1529</start><end>1535</end></extent></part><relatedItem type="host"><titleInfo><title>J Gen Virol</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>1529</start><end>1535</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Anti‐HBs characteristics after hepatitis B immunisation with plasma‐derived and recombinant DNA‐derived vaccines</title></titleInfo><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Heijtink</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Van Bergen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WP</namePart><namePart type="family">Paulij</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RA</namePart><namePart type="family">De Man</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ADME</namePart><namePart type="family">Osterhaus</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Heijtink RA, Van Bergen P, Paulij WP, De Man RA, Osterhaus ADME. 2000. Anti‐HBs characteristics after hepatitis B immunisation with plasma‐derived and recombinant DNA‐derived vaccines. Vaccine 18: 1531–1538.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>1531</start><end>1538</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>1531</start><end>1538</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Hepatitis B surface antigen (HBsAg) subtype‐specific antibodies in persons vaccinated against hepatitis B</title></titleInfo><name type="personal"><namePart type="given">W</namePart><namePart type="family">Jilg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Delhoune</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Deinhardt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AJ</namePart><namePart type="family">Roumeliotou‐Karayannis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GJ</namePart><namePart type="family">Papaevangelou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IK</namePart><namePart type="family">Mushawar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LR</namePart><namePart type="family">Overby</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jilg W, Delhoune C, Deinhardt F, Roumeliotou‐Karayannis AJ, Papaevangelou GJ, Mushawar IK, Overby LR. 1984. Hepatitis B surface antigen (HBsAg) subtype‐specific antibodies in persons vaccinated against hepatitis B. J Med Virol 13: 171–178.</note><part><date>1984</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>171</start><end>178</end></extent></part><relatedItem type="host"><titleInfo><title>J Med Virol</title></titleInfo><part><date>1984</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>171</start><end>178</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Nucleotide sequence of a cloned hepatitis B virus genome subtype ayr: comparison with genomes of the other three subtypes</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Okamoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Imai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Shimozaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Hoshi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Iizuka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Gotanda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Tsuda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Miyakawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Mayumi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Okamoto H, Imai M, Shimozaki M, Hoshi Y, Iizuka H, Gotanda T, Tsuda F, Miyakawa Y, Mayumi M. 1986. Nucleotide sequence of a cloned hepatitis B virus genome subtype ayr: comparison with genomes of the other three subtypes. J Gen Virol 67: 2305–2314.</note><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>2305</start><end>2314</end></extent></part><relatedItem type="host"><titleInfo><title>J Gen Virol</title></titleInfo><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>2305</start><end>2314</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Comparative evaluation of the immunogenicity of yeast‐derived (recombinant) and plasma‐derived hepatitis B vaccine in infants</title></titleInfo><name type="personal"><namePart type="given">SK</namePart><namePart type="family">Panda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Ramesh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KV</namePart><namePart type="family">Rao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Gupta</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AJ</namePart><namePart type="family">Zuckerman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NC</namePart><namePart type="family">Nayak</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Panda SK, Ramesh R, Rao KV, Gupta A, Zuckerman AJ, Nayak NC. 1991. Comparative evaluation of the immunogenicity of yeast‐derived (recombinant) and plasma‐derived hepatitis B vaccine in infants. J Med Virol 35: 297–302.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>297</start><end>302</end></extent></part><relatedItem type="host"><titleInfo><title>J Med Virol</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>297</start><end>302</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Localisation of a unique human HBV epitope sheds new light on the structure of HBsAg</title></titleInfo><name type="personal"><namePart type="given">W</namePart><namePart type="family">Paulij</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PLM</namePart><namePart type="family">De Wit</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CMG</namePart><namePart type="family">Sünnen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MH</namePart><namePart type="family">Van Roosmalen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Petersen‐van Ettekoven</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MP</namePart><namePart type="family">Cooreman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Heijtink</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Paulij W, De Wit PLM, Sünnen CMG, Van Roosmalen MH, Petersen‐van Ettekoven A, Cooreman MP, Heijtink RA. 1999. Localisation of a unique human HBV epitope sheds new light on the structure of HBsAg. J Gen Virol 80: 2121–2126.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>2121</start><end>2126</end></extent></part><relatedItem type="host"><titleInfo><title>J Gen Virol</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>2121</start><end>2126</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Development and characterization of human anti‐HBs antibodies</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Sa'adu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Locniskar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Bidwell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Howard</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KPWJ</namePart><namePart type="family">McAdam</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Voller</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sa'adu A, Locniskar M, Bidwell D, Howard C, McAdam KPWJ, Voller A. 1992. Development and characterization of human anti‐HBs antibodies. J Virol Methods 36: 25–34.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>25</start><end>34</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol Methods</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>25</start><end>34</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Liver transplantation with hepatitis B surface antigen</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Samuel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Muller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Alexander</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Fassati</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Ducot</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Benhamou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Bismuth</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. 1993. Liver transplantation with hepatitis B surface antigen. N Engl J Med 329: 1842–1847.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>329</number></detail><extent unit="pages"><start>1842</start><end>1847</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>329</number></detail><extent unit="pages"><start>1842</start><end>1847</end></extent></part></relatedItem></relatedItem><identifier type="istex">2D0D41BE6B34DA1B0F80FC7647C66386D93201E2</identifier><identifier type="ark">ark:/67375/WNG-F3G8DCGQ-T</identifier><identifier type="DOI">10.1002/jmv.2146</identifier><identifier type="ArticleID">JMV2146</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2002 Wiley‐Liss, Inc.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-15</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-F3G8DCGQ-T/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000584 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000584 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:2D0D41BE6B34DA1B0F80FC7647C66386D93201E2
|texte= Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant‐DNA hepatitis B vaccine
}}
| This area was generated with Dilib version V0.6.33. |  |